# Targeting Epstein–Barr virus is a viable therapeutic strategy in multiple sclerosis: Commentary

**Authors:** Anna Karin Hedström

PMC · DOI: 10.1177/13524585251409951 · 2026-01-14

## Full-text entities

- **Genes:** HLA-A (major histocompatibility complex, class I, A) [NCBI Gene 3105] {aka HLAA}, ANO2 (anoctamin 2) [NCBI Gene 57101] {aka C12orf3, TMEM16B}, HEPACAM (hepatic and glial cell adhesion molecule) [NCBI Gene 220296] {aka GlialCAM, MLC2A, MLC2B}, CRYAB (crystallin alpha B) [NCBI Gene 1410] {aka CMD1II, CRYA2, CTPP2, CTRCT16, HEL-S-101, HSPB5}
- **Diseases:** neuroaxonal injury (MESH:D019150), EBV infection (MESH:D020031), inflammatory (MESH:D007249), ORCID iD (MESH:C535742), MS (MESH:D009103)
- **Species:** Homo sapiens (human, species) [taxon 9606], human gammaherpesvirus 4 (Epstein Barr virus, no rank) [taxon 10376]

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC13036260/full.md

---
Source: https://tomesphere.com/paper/PMC13036260